Voyager Therapeutics Inc (NASDAQ:VYGR)
| 7.37 Delayed Data As of 3:59pm ET |  -0.11 / -1.47%Today’s Change | 4.61 Today|||52-Week Range 10.82 | +20.82% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $342.9M |
Company Description
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.
Contact Information
Voyager Therapeutics, Inc. 64 Sidney Street Cambridge Massachusetts 02139 |
Employees
Shareholders
| Individual stakeholders | 33.16% |
| Other institutional | 31.62% |
| Mutual fund holders | 12.13% |
Top Executives
| Alfred W. Sandrock | President, Chief Executive Officer & Director |
| Robin Swartz | Chief Operating Officer |
| Peter P. Pfreundschuh | Chief Financial & Accounting Officer |
| Todd Carter | Chief Scientific Officer |
| Robert W. Hesslein | Senior Vice President & General Counsel |
